Ivo Machado

Mr. Ivo Machado

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
IMIvo Machado
Ivo Machado
RMRaul Miranda
Raul Miranda
DDDaniel Junqueira Dorta
Daniel Junqueira Dorta
ARAnabela Rolo
Anabela Rolo
Carlos PalmeiraCarlos Palmeira
Carlos Palmeira
Reactive oxygen species (ROS) are important second messengers in many metabolic processes and signaling pathways. Disruption of the balance between ROS generation and antioxidant defenses results in the overproduction of ROS and subsequent oxidative damage to biomolecules and cellular components that disturb cellular function. Oxidative stress contributes to the initiation and progression of many liver pathologies such as ischemia-reperfusion injury (LIRI), non-alcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC). Therefore, controlling ROS production is an attractive therapeutic strategy in relation to their treatment. In recent years, increasing evidence has supported the therapeutic effects of polyphenols on liver injury via the regulation of ROS levels. In the current review, we summarize the effects of polyphenols, such as quercetin, resveratrol, and curcumin, on oxidative damage during conditions that induce liver injury, such as LIRI, NAFLD, and HCC.

20 November 2019 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
IMIvo Machado
Ivo Machado
João TeodoroJoão Teodoro
João Teodoro
Carlos PalmeiraCarlos Palmeira
Carlos Palmeira
ARAnabela Rolo
Anabela Rolo

16 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
João TeodoroJoão Teodoro
João Teodoro
RSRui Silva
Rui Silva
IMIvo Machado
Ivo Machado
Arnau Panisello-RosellóArnau Panisello-Roselló
Arnau Panisello-Roselló
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
Carlos PalmeiraCarlos Palmeira
Carlos Palmeira
Hepatic ischemia reperfusion injury (HIRI) is a major hurdle in many clinical scenarios, including liver resection and transplantation. Various studies and countless surgical events have led to the observation of a strong correlation between HIRI induced by liver transplantation and early allograft-dysfunction development. The detrimental impact of HIRI has driven the pursuit of new ways to alleviate its adverse effects. At the core of HIRI lies mitochondrial dysfunction. Various studies, from both animal models and in clinical settings, have clearly shown that mitochondrial function is severely hampered by HIRI and that its preservation or restoration is a key indicator of successful organ recovery. Several strategies have been thus implemented throughout the years, targeting mitochondrial function. This work briefly discusses some the most utilized approaches, ranging from surgical practices to pharmacological interventions and highlights how novel strategies can be investigated and implemented by intricately discussing the way mitochondrial function is affected by HIRI.

20 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
IMIvo Machado
Ivo Machado
Carlos PalmeiraCarlos Palmeira
Carlos Palmeira
ARAnabela Rolo
Anabela Rolo
Liver ischemia-reperfusion injury (LIRI) is a major cause of the development of complications in different clinical settings such as liver resection and liver transplantation. Damage arising from LIRI is a major risk factor for early graft rejection and is associated with higher morbidity and mortality after surgery. Although the mechanisms leading to the injury of parenchymal and non-parenchymal liver cells are not yet fully understood, mitochondrial dysfunction is recognized as a hallmark of LIRI that exacerbates cellular injury. Mitochondria play a major role in glucose metabolism, energy production, reactive oxygen species (ROS) signaling, calcium homeostasis and cell death. The diverse roles of mitochondria make it essential to preserve mitochondrial health in order to maintain cellular activity and liver integrity during liver ischemia/reperfusion (I/R). A growing body of studies suggest that protecting mitochondria by regulating mitochondrial biogenesis, fission/fusion and mitophagy during liver I/R ameliorates LIRI. Targeting mitochondria in conditions that exacerbate mitochondrial dysfunction, such as steatosis and aging, has been successful in decreasing their susceptibility to LIRI. Studying mitochondrial dysfunction will help understand the underlying mechanisms of cellular damage during LIRI which is important for the development of new therapeutic strategies aimed at improving patient outcomes. In this review, we highlight the progress made in recent years regarding the role of mitochondria in liver I/R and discuss the impact of liver conditions on LIRI.

Verified
Journal Article
Open access
PDF file
RSRui Silva
Rui Silva
IMIvo Machado
Ivo Machado
João TeodoroJoão Teodoro
João Teodoro
Arnau Panisello-RosellóArnau Panisello-Roselló
Arnau Panisello-Roselló
Joan Rosello-CatafauJoan Rosello-Catafau
Joan Rosello-Catafau
Carlos PalmeiraCarlos Palmeira
Carlos Palmeira
Pharmacological conditioning is a protective strategy against ischemia/reperfusion injury, which occurs during liver resection and transplantation. Polyethylene glycols have shown multiple benefits in cell and organ preservation, including antioxidant capacity, edema prevention and membrane stabilization. Recently, polyethylene glycol 35 kDa (PEG35) preconditioning resulted in decreased hepatic injury and protected the mitochondria in a rat model of cold ischemia. Thus, the study aimed to decipher the mechanisms underlying PEG35 preconditioning-induced protection against ischemia/reperfusion injury. A hypoxia/reoxygenation model using HepG2 cells was established to evaluate the effects of PEG35 preconditioning. Several parameters were assessed, including cell viability, mitochondrial membrane potential, ROS production, ATP levels, protein content and gene expression to investigate autophagy, mitochondrial biogenesis and dynamics. PEG35 preconditioning preserved the mitochondrial function by decreasing the excessive production of ROS and subsequent ATP depletion, as well as by recovering the membrane potential. Furthermore, PEG35 increased levels of autophagy-related proteins and the expression of genes involved in mitochondrial biogenesis and fusion. In conclusion, PEG35 preconditioning effectively ameliorates hepatic hypoxia/reoxygenation injury through the enhancement of autophagy and mitochondrial quality control. Therefore, PEG35 could be useful as a potential pharmacological tool for attenuating hepatic ischemia/reperfusion injury in clinical practice.

2 May 2025 in Ageing Research Reviews
Verified
Journal Article
Closed access
IMIvo Machado
Ivo Machado
CPCarlos M. Palmeira
Carlos M. Palmeira
ARAnabela Rolo
Anabela Rolo